Previous close | 1,437.80 |
Open | 0.00 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 0.00 - 0.00 |
52-week range | |
Volume | |
Avg. volume | 10,053,936 |
Market cap | 58.877B |
Beta (5Y monthly) | 0.27 |
PE ratio (TTM) | 13.22 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 0.61 (4.26%) |
Ex-dividend date | 23 Feb 2023 |
1y target est | N/A |
PHILADELPHIA, March 14, 2023--GSK and Earvin "Magic" Johnson Partner to Raise Awareness of Risk of RSV in Older Adults
A GSK-sponsored Ipsos-MORI survey revealed only 3% of Singaporeans aged 50-79 years believe they are at high risk of developing shingles in the next 12 months. The survey among 200 respondents further reported that while 40% believe shingles is serious, only 6% spoke to a healthcare professional (HCP) about protection against the disease.
GSK Singapore today announced that Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5), has been approved for treatment in patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) and hypereosinophilic syndrome (HES)[1]. These new indications for mepolizumab are for the add-on maintenance treatment of severe CRSwNP in adult patients 18 years of age and older with inadequate response to nasal corticosteroids, and for adult patients with inadequately control